Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Cellectis, a clinical-stage biotechnology company, announced the appointment of two new Directors, Axel-Sven Malkomes and Donald Bergstrom, M.D., Ph.D., during its annual shareholders meeting on June 28, 2022. Both appointees bring extensive experience from the healthcare and financial sectors. Dr. Bergstrom serves as Executive Vice President at Relay Therapeutics and has previous roles at Mersana Therapeutics and Sanofi Oncology. Mr. Malkomes has over 25 years in the industry, previously serving as CFO at Medigene AG and holding senior positions at Barclays and Société Générale.
Cellectis S.A. hosted its Annual Shareholders’ General Meeting on June 28, 2022, in Paris, France, with 67.23% of voting rights exercised.
Resolutions 1 through 23 and 25 were approved, while resolutions 24 and 26 were rejected. Detailed voting results are available on the company's website.
Cellectis is a clinical-stage biotech company focused on developing gene therapies for various cancers and blood disorders using its TALEN gene-editing technology and PulseAgile system.
Cellectis, a clinical-stage biotechnology company, focuses on gene-editing therapies for cancer and blood disorders. As of May 31, 2022, the company has 45,510,810 shares and 51,103,546 voting rights. Utilizing TALEN® gene editing technology, Cellectis aims to develop allogeneic CAR-T immunotherapies for conditions like acute myeloid leukemia and multiple myeloma. With over 22 years of expertise, it is dedicated to creating transformative therapies. The company is listed on both the Nasdaq (CLLS) and Euronext Growth (ALCLS).
Cellectis (Nasdaq: CLLS), a biotechnology firm focused on gene-editing therapies, will conduct its combined general meeting on June 28, 2022, at 2:30 p.m. CET in Paris. The meeting will cover key agenda items and participation details available on their website. Cellectis employs CAR-T immunotherapies and TALEN technology to develop treatments for various cancers and genetic disorders. With over 22 years of experience in gene editing, the company aims to deliver innovative therapies and remains dedicated to addressing unmet medical needs in oncology.
Cellectis, a clinical-stage biotechnology company, presented groundbreaking research at the American Society of Cell and Gene Therapy Annual Meeting on May 16, 2022. The data focuses on a novel universal CAR T-cell, ΔTRACCARΔB2MHLAE, designed with immune-evasive properties via TALEN® gene editing. This IMMUNO-evasive CAR T-cell effectively evades attacks from NK cells and alloresponsive T-cells, demonstrating prolonged antitumor activity in vitro and in vivo. The findings indicate promising avenues for allogeneic CAR T-cell therapies.
Cellectis, a clinical-stage biotechnology company, reported significant progress in Q1 2022, with a cash position of $142 million expected to fund operations into early 2024. The company presented robust preclinical data for UCART20x22 and published key validations for UCART123 in Nature Communications. Cellectis received a $20 million convertible note from Cytovia Therapeutics as part of their collaboration. However, Q1 revenues plummeted to $4 million from $28 million, leading to a net loss of $32 million. The company maintains focus on advancing its CAR T platform and seeks to file an IND for UCART20x22.
Cellectis, a clinical-stage biotechnology company, continues to develop gene-editing therapies for cancer and blood disorders. As of April 30, 2022, Cellectis reported a total of 45,510,810 shares in capital and 51,103,431 voting rights. The company focuses on allogeneic CAR-T therapies and novel approaches in gene editing using TALEN® technology. Cellectis aims to provide lifesaving treatments for conditions like acute myeloid leukemia and multiple myeloma while maintaining a commitment to address unmet medical needs.
Cellectis, a clinical-stage biotechnology company specializing in gene-editing, has announced its financial results for Q1 2022 will be released on May 12, 2022. A conference call is scheduled for May 13, 2022, at 8:00 AM EDT to discuss these results and provide a business update. Cellectis focuses on developing innovative CAR-T immunotherapies using its TALEN® gene editing technology and PulseAgile electroporation system. The company operates in the U.S. and France and is listed on Nasdaq under the ticker CLLS.
Cellectis S.A. (NASDAQ: CLLS) has announced Calyxt, its subsidiary, reported first-quarter 2022 results. Calyxt generated nominal revenue due to the discontinuation of its soybean product line, down from $4.4 million in Q1 2021. Operating expenses fell to $6.1 million, resulting in a net loss of $5.6 million compared to $10.0 million in the previous year. Calyxt's advancements include evaluating 28 customer-identified molecules and enhancing its BioFactory production capabilities, as well as raising $10 million from a stock offering, which will support technology scaling and customer engagement.
Cellectis has published promising preclinical data regarding its gene-edited CAR T-cell therapy candidate, UCART123, targeting acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Results demonstrate that UCART123 effectively eliminates AML cells with minimal impact on normal hematopoietic progenitor cells, supporting its clinical evaluation in the ongoing Phase 1 AMELI-01 trial. The therapy has shown potent anti-BPDCN activity and improved overall survival in patient-derived models, enhancing its potential as a treatment option for patients with unmet medical needs.